Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cost of Revenue (2016 - 2025)

Cumberland Pharmaceuticals' Cost of Revenue history spans 16 years, with the latest figure at $14.7 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 17.51% year-over-year to $14.7 million; the TTM value through Dec 2025 reached $19.1 million, down 5.32%, while the annual FY2025 figure was $19.1 million, 12.19% up from the prior year.
  • Cost of Revenue for Q4 2025 was $14.7 million at Cumberland Pharmaceuticals, up from $988760.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $14.7 million in Q4 2025 and bottomed at -$4.2 million in Q4 2022.
  • The 5-year median for Cost of Revenue is $4.1 million (2021), against an average of $4.2 million.
  • The largest YoY upside for Cost of Revenue was 209.51% in 2022 against a maximum downside of 143.69% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $9.5 million in 2021, then crashed by 143.69% to -$4.2 million in 2022, then surged by 202.75% to $4.3 million in 2023, then surged by 191.92% to $12.5 million in 2024, then rose by 17.51% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Cost of Revenue are $14.7 million (Q4 2025), $988760.0 (Q3 2025), and -$794877.0 (Q2 2025).